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Summan In some clinical situations the endogenous production of glutamine may be insufficient to maintain
optimal tissue structure and function such that glutamine becomes a conditionallv essential amino acid.
Studies in laboratory animals have demonstrated that glutamine supplementation can reduce the incidence and
severty of cytotoxic-induced mucositis. This study examined the role of oral glutamine supplementation in the
management of mucositis caused by 5-fluorouracil (5-FU) and folinic acid. Twenty-eight patients with
gastrointestinal cancers were randomised to receive 16 g of glutamine per day for 8 days. or placebo. in a
randomised double-blind trial before crossing over to the alternative supplement during the second treatment
cycle. The supplement was well tolerated with no apparent adverse effects. but failed to have any significant
effect on oral mucositis assessed by the patients or investigator. The possible reasons for this apparent lack of
benefit are discussed.
Mucositis is a common and sometimes dose-limiting effect of
chemotherapy. In patients receiving 5-FU and folinic acid it
has been estimated that as many as 80% may develop
mucositis, with 26% experiencing severe mucositis (Poon et
al.. 1989). It is both physically and psychologically distressing
to the patient and not uncommonly leads to a reduction in
dose intensity. Supportive care measures to diminish the
incidence or severity of mucositis would have obvious clinical
benefits. Allopurinol (Clark & Slevin. 1985) and cryotherapy
(Mahood et al.. 1991) have both been suggested, but neither
has demonstrated sufficient efficacy to become part of stan-
dard clinical practice. Recent work in animals suggests that
the administration of glutamine may be a more promising
solution.
Glutamine is the most abundant amino acid in the blood
and in the free amino acid pool of the body (Bergstrom et
al.. 1974) and its flux between tissues is greater than any
other amino acid (Elia, 1991). It is becoming increasingly
apparent that glutamine plays a pivotal role in intermediary
metabolism (Smith. 1990). It is an important fuel for the
mucosal cells of the gut (Windmueller & Spaeth. 1985) and a
variety of other rapidly dividing cells, such as lymphocytes
and macrophages (Newsholme et al., 1988). In addition, it is
a precursor for nucleic acid synthesis (Krebs, 1980).
In several animal studies glutamine administration has
been shown to lead to a reduction in the morbidity and
mortality of animals treated with cytotoxic agents. Benefits
have been observed with both parenteral and enteral admini-
stration of glutamine with a variety of chemotherapeutic
agents including methotrexate (Fox et al.. 1988) and 5-FU
(O'Dwsyer et al.. 1987). In addition to the preservation of the
morphological structure of the gut there was a significant
reduction in the incidence of bacteraemia and improved sur-
vival (Fox et al.. 1988).
Dose-response studies in healthy human volunteers have
confirmed the safety of glutamine given both orally and
intravenously (Ziegler et al.. 1990), and in vitro studies
suggest that it does not increase tumour growth (Klimberg et
al.. 1990). We have performed a pilot study to assess the
feasibility of oral glutamine supplementation in patients with
gastrointestinal cancers receiving 5-FU and foliic acid and
to determine its effect on the incidence and severity of
mucositis. particularly in the oral cavity.
Materials and methods
Twenty-eight patients with advanced. metastatic. gastrointes-
tinal cancers were studied. The primary sites were stomach
(three male). colon (11 male. six female), rectum (five male).
pancreas (one female), gall bladder (one female) and un-
known (one male). Patients received folinic acid (20 mg m-)
as an intravenous bolus dose followed immediately by an
intravenous bolus of 5-fluorouracil (400 or 425 mg m-2) daily
for 5 days and repeated 4 weeks from the start of treat-
ment.
Patients were randomised to receive either glutamine or
placebo with the first cycle of treatment and the alternative
supplement with cycle 2. such that each patient could act as
his or her own control. The glutamine supplement comprised
16 g of glutamine (BDH) daily. which was divided into four
equal doses and taken at intervals during the day. usually
after meals and before bed. The placebo was Polycal (Cow &
Gate. Nutricia). a glucose polymer, given to the same
schedule. Both supplements were presented in individual
sachets, to be dissolved in 150ml of water or other cold
fluids immediately prior to consumption. Patients were in-
structed to use the drink as a mouthwash prior to swallow-
ing. Supplementation began 24 h prior to treatment and
continued for a total of 8 days. ending 48 h after the final
infusion of chemotherapy. Patients and investigator were
unaware of the randomisation order for each subject.
The patients recorded the number of sachets of supplement
consumed each day and also completed a diary card beginn-
ing on the first day of supplementation and continuing daily
for 28 days, which included an assessment of oral mucositis.
number of bowel motions and stool consistency (Table I).
The number and nature of admissions to hospital between
cycles of treatment was noted along with the response to
therapy. An observer assessment of maximal mucositis was
made at the end of each cycle according to the WHO
classification. Differences between glutamine and placebo
supplemented treatment cycles were assessed using Student's
paired t-test.
The serum concentration of glutamine was investigated on
day 5 of the first cycle in a subgroup of ten patients. The
patients were asked to fast overnight and a pretreatment
serum sample obtained the following morning (09.00 h) 5 min
before administration of the 4g of glutamine or placebo
supplement. A standard breakfast was given after 60 min. the
chemotherapy after 150 min and lunch plus a second 4 g
supplement of the same compound after 200 min. Thirteen
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Table I Scoring system for patient-reported symptoms
.Uouth comfort Ease of eating Stool consistency
I No change from normal I Eating as normal 1 Normal stools
2 Slightly sore mouth 2 Eating is uncomfortable 2 Soft but formed stools
3 Sore mouth 3 Pain on chewing 3 Unformed stools
4 Painful mouth with ulcers 4 Soft food or liquids only 4 Watery stools
5 Severe pain with ulcers and 5 Unable to eat or drink 5 Watery and blood-stained
inflammation stools
sequential serum samples were collected over the 300 mn
study period. Samples were analysed for glutamine by
reversed-phase high-performance liquid chromatography
(HPLC) using the fluorescent method of Lindroth and
Mopper (1979) and employing the modification suggested by
Alfredsson et al. (1988). All reagents used in this assay were
obtained from Sigma. Poole. Dorset. UK.
Results
Of the 28 patients entered into the study 17 patients com-
pleted two cycles of treatment and are included in the subse-
quent evaluation. Of the remainder. six patients died before
the second cycle was due (four glutamine. two placebo), of
which four deaths were attributed to treatment toxicity (two
glutamine, two placebo). At the end of the first cycle of
treatment five patients had evidence of progressive disease
and treatment was either changed or withdrawn (one gluta-
mine, four placebo). At the end of two cycles of treatment
one patient had achieved a partial response. 13 patients had
static disease and three had evidence of progressive disease.
These results from treatment reflect the advanced stage of
disease in this patient group.
The supplements were virtually tasteless and well tolerated
by all patients. with no apparent adverse effects. The mean
(s.d.) consumption of the dose was 93% (11%) of that
prescribed.
The observer assessment of oral toxicity. according to the
WHO classification, is shown in Figure 1. The differences
between treatment cycles were small. Overall, nine patients
experienced some mucositis (WHO mucositis score >2) and
four patients experienced severe mucositis (WHO mucositis
score > 3) during the first cycle of treatment and eight and
five patients respectively in the second cycle. The figures for
treatment with and without glutamine were similar (seven
and five patients with glutamine and ten and four patients
with placebo).
The mean symptom scores from the diary cards for the 17
patients who completed two courses of treatment are shown
in Table II. They revealed no significant difference in the
severity of oral mucositis. number of bowel motions or stool
consistency between glutamine- and placebo-supplemented
treatments.
There was no significant difference in haematological tox-
icity in nine patients who had full blood counts on day 15 of
each cycle (Table III). Patients were admitted to hospital
between treatment cycles on only two occasions (one
glutamine. one placebo).
The mean (s.d.) serum glutamine levels at time zero were
0.53 (0.06) gM for the patients receiving oral glutamine and
0.68 (0.20) ,4m for the placebo group. These means were not
significantly different (P = 0.3). The time course of serum
glutamine for the ten patients is shown in Figure 2. Patient 1
showed a 2-fold rise in glutamine concentration after the
initial glutamine dose, which reached a peak value of 1.33 tM
within 15 min and declined with a half-life of 17 min. Basal
levels were achieved after 60 min. No such concomitant
change in glutamine concentration was observed after lunch
supplemented with glutamine. In the other four patients no
definitive increase in serum concentration was detected after
glutamine dosing. Minimal changes in serum glutamine levels
were associated with the placebo dosing.
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Table 11 Mean±s.d. patient-reported symptom scores
Syvmptom Glutamine Placebo
Mouth comfort 1.56 ± 0.66 1.52 ± 0.62 NS
Ease of eating 1.40 0.57 1.36 0.48 NS
Stool consistency 1.87 0.76 1.90 0.81 NS
No. of stools dav 1.62 ± 0.93 1.80 ± 0.98 NS
See Table I.
Table III Mean ± s.d. haematological indices (n = 9)
Day Glutamine Placebo
Haemaglobin 0 11.98 ± 1.37 11.88 ± 0.85 NS
(g 1-) 15 11.06±1.20 11.71 1.19 NS
29 11.64 1.08 11.99 1.31 NS
WBC 0 6.70 3.13 6.98 3.96 NS
(X 1091-1) 15 4.85±2.53 4.89±2.10 NS
29 8.00 ± 4.67 7.09 ± 4.67 NS
Platelets 0 268 ± 123 263 ± 107 NS
(X 1091 I) 15 203 107 182 110 NS
29 249±106 214±119 NS734 S.A. JEBB et al.
DEscuss
The administration of this chemotherapy regimen to patients
with gastrointestinal cancers was associated with similar gast-
rointestinal toxicity to that previously reported by Poon et al.
(1989). However, in this small study the anticipated benefits
of glutamine in reducing the incidence or severity of
mucositis have not been fulfilled despite the strong rationale,
based on previous animal studies. While this study goes
against a growing body of evidence of a variety of clinical
benefits attributable to glutamine or its metabolites a-
ketoglutarate and ornithine ketoglutarate, it was deemed
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inappropriate to continue with the study in its present for-
mat. Several hypotheses can be raised to account for this lack
of effect which must be addressed in future studies.
In the majority of previous human studies glutamine has
been administered intravenously (e.g. Ziegler et al., 1990).
although evidence from animal studies suggests that similar
decreases in the incidence and severity of mucositis occur
with enteral glutamine supplementation (Fox et al.. 1988). To
date most studies have considered the impact ofglutamine on
the large bowel, and this is the first study to have specifically
addressed the issue of oral mucositis. In the normal state the
mucosal cells of the gut receive glutamine both from the gut
lumen and from the systemic circulation. In the oral cavity
the latter is the predominant source. We hypothesised that by
using the glutamine solution as a mouthwash free glutamine
would be made available for uptake by the cells of the oral
mucosa and reduce the severity or duration of mucositis.
However, this did not occur. It is possible that either these
stratified squamous cells do not exhibit the preference for
glutamine as a fuel demonstrated by enterocytes and col-
onocytes or that the duration of exposure to glutamine was
too short. Pharmacokinetic studies of glutamine administra-
tion to healthy subjects have shown a significant increase in
plasma gutamine concentrations with oral doses of 0.1 g kg-'
body weight or greater (Ziegler et al.. 1990). No such inc-
reases were measured in a subgroup of these patients when
the supplement was given following an overnight fast or with
a meal. Hence. no additional benefit to the oral mucosa
would be anticipated from the supply of glutamine via the
systemic circulation.
The dose of glutamine given in this study (4.13 g of nit-
rogen) must also be considered. This dose was similar to the
dose used in animals (as a proportion of total nitrogen
intake) and shown to have a beneficial effect on the intestinal
mucosa. However. recent human studies which have shown
positive benefits have given 0.57 g of glutamine per kg, more
than twice the dose in this study (Ziegler et al., 1992;
Schloerb & Amare. 1993), and via the intravenous route.
Increasing the dose of glutamine via the oral route is not
easy. The solubility of glutamine is only 3.6% at 23°C (Elia,
1992). Hence, a dose of 16g requires over 400ml of fluid.
This is a significant burden to patients, who are often
anorexic and suffer from oral mucositis.
This study differed from many others, both animal and
human, in the attention given to clinical end points. Studies
in laboratory animals receiving cytotoxic agents who have
received glutamine-enriched diets have generally focused on
the effects on the gut in terms of the maintenance of mucosal
structure, and have inferred that preservation of the gut
structure will lead to improvements in clinical end points. In
clinical studies nitrogen balance is commonly used as a
marker of clinical benefit, yet a direct relationship between
the two has yet to be shown. In the study of Ziegler et al.
(1992) in which intravenous glutamine supplementation was
given to patients receiving bone marrow transplants. there
was an improvement in nitrogen balance at a dose of
0.57 g kg-', which was not observed at the lower dose rate of
0.285 g kg-', but the direct clinical relevance of this is un-
clear. There was also a significant reduction in sepsis. shown
by a decrease in the number of positive cultures, but there
was no reduction in oral mucositis. In our study improve-
ments in gut structure and nitrogen balance cannot be ruled
out, but with respect to the principal clinical end point in this
study, that of oral mucositis, there was no apparent effect of
glutamine supplementation. Clearly, further evaluation is
required of the potential role of glutamine supplementation
in the management of cytotoxic-induced mucositis in terms
of the most appropriate dose of glutamine. route of supple-
mentation and clinically relevant markers of benefit. A better
understanding of the mechanism of glutamine action, which
is currently unclear, can only assist the rational application
of this nutritional pharmacology.
We would like to thank Gail Goldberg. who supervised the ran-
domisation of the patients in this study.
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